- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Egetis Therapeutics AB (publ) (EGTX)
Egetis Therapeutics AB (publ) stock price live, this page displays ST EGTX stock exchange data. View the EGTX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Egetis Therapeutics AB (publ) real time stock price chart below.
What Is the Egetis Therapeutics AB (publ) Stock Price Today?
The Egetis Therapeutics AB (publ) stock price today is 3.23.
What Is the Stock Symbol for Egetis Therapeutics AB (publ)?
The stock symbol for Egetis Therapeutics AB (publ) is "EGTX."
What Stock Exchange Does Egetis Therapeutics AB (publ) Trade On?
Egetis Therapeutics AB (publ) is listed and trades on the Stockholm stock exchange.
Is Egetis Therapeutics AB (publ) a Good Stock to Buy?
Determining whether Egetis Therapeutics AB (publ)—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EGTX quote. (ISIN: SE0003815604)
What Is the Egetis Therapeutics AB (publ) Stock Price Today?
The Egetis Therapeutics AB (publ) stock price today is 3.23.
What Is the Stock Symbol for Egetis Therapeutics AB (publ)?
The stock symbol for Egetis Therapeutics AB (publ) is "EGTX."
What Stock Exchange Does Egetis Therapeutics AB (publ) Trade On?
Egetis Therapeutics AB (publ) is listed and trades on the Stockholm stock exchange.
Is Egetis Therapeutics AB (publ) a Good Stock to Buy?
Determining whether Egetis Therapeutics AB (publ)—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EGTX quote. (ISIN: SE0003815604)
Stockholm
Currency in SEK
3.23
0.00(0.00%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.15
3.28
52 wk Range
3.15
9.30
EGTX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Trading near 52-week Low
More Info
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.153.28
52 wk Range
3.159.30
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
EGTX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
12.00
Upside
+271.52%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Egetis Therapeutics AB (publ) Company Profile
Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. The company’s products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol overdose, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, a debilitating rare disease with no available treatment. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.
Egetis Therapeutics AB (publ) Earnings Call Summary for Q1/2025
- Q1 2025 revenue up to SEK 12.7M from SEK 12.1M YoY; gross profit margin impacted by royalty payments
- MC Tate launch in Germany set for May 1, 2025; US launch preparations ongoing with NDA submission planned for 2025
- Cash position improved to SEK 273M; operating cash flow at -SEK 66.1M
- Analysts project 233% revenue growth for FY2025; company not expected to achieve profitability this year
- CEO optimistic about European launch; potential challenges include US regulatory hurdles and pharmaceutical tariffs
Last Updated: 30/04/2025, 07:00 pm
Read Full TranscriptCompare EGTX to Peers and Sector
Metrics to compare | EGTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEGTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.5x | −13.7x | −0.5x | |
PEG Ratio | −0.16 | 0.00 | 0.00 | |
Price/Book | 2.7x | 7.8x | 2.6x | |
Price / LTM Sales | 24.7x | 59.5x | 3.0x | |
Upside (Analyst Target) | 256.0% | −22.9% | 54.7% | |
Fair Value Upside | Unlock | 7.1% | 8.4% | Unlock |
Analyst Ratings
3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 12.00
(+271.52% Upside)
Earnings
Latest Release
Apr 30, 2025
EPS / Forecast
-0.17 / -0.19
Revenue / Forecast
12.70M / 24.70M
People Also Watch
FAQ
What Is the Egetis Therapeutics AB (EGTX) Stock Price Today?
The Egetis Therapeutics AB stock price today is 3.23
What Stock Exchange Does Egetis Therapeutics AB Trade On?
Egetis Therapeutics AB is listed and trades on the Stockholm Stock Exchange stock exchange.
What Is the Stock Symbol for Egetis Therapeutics AB?
The stock symbol for Egetis Therapeutics AB is "EGTX."
What Is the Egetis Therapeutics AB Market Cap?
As of today, Egetis Therapeutics AB market cap is 1.16B.
What Is Egetis Therapeutics AB's Earnings Per Share (TTM)?
The Egetis Therapeutics AB EPS (TTM) is -1.03.
When Is the Next Egetis Therapeutics AB Earnings Date?
Egetis Therapeutics AB will release its next earnings report on 20 Aug 2025.
From a Technical Analysis Perspective, Is EGTX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.